GlassScriptPhysician profile
Varun Shah
NPI 1538573480
$63,772.87
in general payments reported to CMS, 2019-2025
36 companies · $24K in 2025
The $24K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2021: $593 · 2022: $2,398 · 2023: $15K · 2024: $21K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $21K · Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $9,852 · Education: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $20,695.91 |
| Consulting Fee | $16,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,000.00 |
| Food and Beverage | $9,852.17 |
| Education | $1,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $35,079.62 | 2021-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Pulmonx Corporation | $20,526.27 | 2022-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Astrazeneca Pharmaceuticals LP | $1,692.69 | 2022-2025 | Tezspire, Airsupra, Fasenra |
| Siemens Medical Solutions USA, INC. | $1,212.36 | 2025 | Cios Spin |
| Glaxosmithkline, LLC. | $797.46 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $744.63 | 2021-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $502.56 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mylan Specialty L.P. | $413.97 | 2019-2023 | Yupelri |
| Galvanize Therapeutics, INC | $380.94 | 2023-2025 | Aliya System |
| Insmed, INC. | $259.32 | 2022-2024 | Arikayce |
| Genzyme Corporation | $231.44 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $186.82 | 2024-2025 | Dupixent |
| Medtronic, INC. | $183.49 | 2021-2023 | Illumisite |
| Serpex Medical INC | $172.43 | 2025 | |
| Grifols USA, LLC | $157.69 | 2021-2025 | Prolastin-C Liquid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $124.03 | 2025 | Uptravi, Opsumit, Opsynvi |
| Baxter Healthcare | $108.73 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Ucb, INC. | $99.98 | 2023 | Briviact |
| Fujifilm Healthcare Americas Corporation | $95.24 | 2024 | Fujifilm |
| Merck Sharp & Dohme LLC | $94.24 | 2025 | Keytruda, Zerbaxa |
| Verona Pharma, INC. | $90.18 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $76.80 | 2022-2024 | Glassia |
| Merit Medical Systems INC | $76.65 | 2022 | |
| Viatris Specialty LLC | $76.40 | 2025 | Yupelri |
| Olympus America INC. | $61.87 | 2022-2025 | |
| Philips North America LLC | $49.75 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| United Therapeutics Corporation | $47.65 | 2024-2025 | Tyvaso, Tyvaso |
| La Jolla Pharmaceutical Company | $44.55 | 2025 | Giapreza |
| Inogen, INC. | $35.85 | 2022 | |
| Mallinckrodt Hospital Products INC. | $27.68 | 2025 | Acthar |
| Cmp Pharma, INC. | $26.55 | 2023 | Tadliq |
| Ethicon INC. | $25.30 | 2021 | |
| Ani Pharmaceuticals, INC. | $20.77 | 2024 | Purified Cortrophin Gel |
| Shionogi INC | $20.22 | 2023 | Fetroja |
| Janssen Pharmaceuticals, INC | $14.64 | 2022 | |
| Electromed, INC. | $14.10 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varun Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.